Redhill Biopharma (STU:2RH) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma COGS-to-Revenue?

Redhill Biopharma's Cost of Goods Sold for the three months ended in Dec. 2024 was €0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was €0.00 Mil.

Redhill Biopharma's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Redhill Biopharma's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

Redhill Biopharma COGS-to-Revenue Historical Data

The historical data trend for Redhill Biopharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma COGS-to-Revenue Chart

Redhill Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.57

0.58

0.54

0.53

0.40

Redhill Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.45	0.45	-	-	-

Redhill Biopharma COGS-to-Revenue Calculation

Redhill Biopharma's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.048	/	7.681
	=	0.40

Redhill Biopharma's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Redhill Biopharma (STU:2RH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Redhill Biopharma's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Redhill Biopharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

RDHL:USA

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Redhill Biopharma Headlines

No Headlines